Bromhexine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Bromhexine: From Respiratory Mucolytic Use to Vulvitis
One-Sentence Summary
Bromhexine is a mucolytic (a drug that thins airway mucus) that is marketed in Singapore in tablet, elixir, syrup and cough-liquid products. The TxGNN model predicts it may be effective for vulvitis, but no clinical trials and no publications currently support this prediction. The prediction rests only on a knowledge-graph score and should be treated as a hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore license records (the products are mucolytic/cough preparations) |
| Predicted New Indication | Vulvitis |
| TxGNN Prediction Score | 83.75% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 11 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Bromhexine is generally known as a mucolytic that thins respiratory mucus, and it has also been described as a TMPRSS2 inhibitor.
Neither activity has a recognized link to inflammation or infection of the vulvar mucosa. The prediction is better read as a knowledge-graph artifact than as a mechanism-based hypothesis. Several of the top predictions (vulvitis, vaginitis, vulvovaginitis, ulceration of vulva) cluster around the same genital-tract area. This suggests one shared graph-neighbourhood signal rather than independent pieces of evidence.
The remaining top-10 predictions, such as bacterial vaginosis, vulvar neoplasm and a hair condition (catatrichy), also lack any identified mechanistic rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for vulvitis.
For reference, the only literature found among the top-10 predictions concerns a different prediction, irritable bowel syndrome (rank 5):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28860846 | 2017 | Review | Journal of Pain Research | Discusses ambroxol (the active metabolite of bromhexine) in fibromyalgia. It is a different condition and gives only indirect relevance to irritable bowel syndrome. |
Singapore Market Information
All 11 licenses are valid single-ingredient products. The approved indication text is not recorded in the licence data for any of them.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN02479P | Bromhexine Tablet 8 mg | Tablet | Not stated |
| SIN10906P | Axcel Bromhexine Tablet 8 mg | Tablet | Not stated |
| SIN02468P | Bromhexine Elixir 4 mg/5 ml | Elixir | Not stated |
| SIN02846P | Mucolix Elixir 4 mg/5 ml | Elixir | Not stated |
| SIN10014P | Duro-Tuss Chesty Cough Liquid | Solution | Not stated |
Six further licenses are also held, for Bromxine, Vasican (tablet and syrup), Hosolvon, Mucosol and Bislan products.
Safety Considerations
Please refer to the package insert for safety information.
No drug-interaction records were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for vulvitis has no clinical trials, no publications and no plausible mechanistic link. It relies only on a knowledge-graph score, which corresponds to evidence level L5. The drug is already widely marketed in Singapore, but only for non-genital uses.
To proceed, the following is needed:
- Mechanism of action data for bromhexine, and any rationale for activity on vulvar mucosa
- Package insert warnings and contraindications from the Singapore regulator (HSA)
- Approved indication text for the licensed products
- Preclinical or early clinical data for vulvitis, or a review of whether a topical route would be required (route compatibility has not yet been assessed)
- A check of whether the clustered genital-tract predictions represent an independent signal or a single artifact
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.